JP2011528030A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528030A5 JP2011528030A5 JP2011518009A JP2011518009A JP2011528030A5 JP 2011528030 A5 JP2011528030 A5 JP 2011528030A5 JP 2011518009 A JP2011518009 A JP 2011518009A JP 2011518009 A JP2011518009 A JP 2011518009A JP 2011528030 A5 JP2011528030 A5 JP 2011528030A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- acceptable salt
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 14
- 238000000634 powder X-ray diffraction Methods 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 238000011282 treatment Methods 0.000 claims 8
- 230000004048 modification Effects 0.000 claims 6
- 238000012986 modification Methods 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000006239 protecting group Chemical group 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims 3
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 238000002648 combination therapy Methods 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- BOBWGIWRWAIVDW-PBHICJAKSA-N C[C@H]([C@H]1OC(C)(C)OC1)Nc1cc(NS(N2CCC2)(OC)=O)nc(SCc(cccc2F)c2F)n1 Chemical compound C[C@H]([C@H]1OC(C)(C)OC1)Nc1cc(NS(N2CCC2)(OC)=O)nc(SCc(cccc2F)c2F)n1 BOBWGIWRWAIVDW-PBHICJAKSA-N 0.000 description 1
- 0 C[C@]([C@]1O*OC1)Nc1cc(C)nc(SCc2cccc(F)c2F)n1 Chemical compound C[C@]([C@]1O*OC1)Nc1cc(C)nc(SCc2cccc(F)c2F)n1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8121308P | 2008-07-16 | 2008-07-16 | |
| US61/081,213 | 2008-07-16 | ||
| PCT/GB2009/050856 WO2010007427A1 (en) | 2008-07-16 | 2009-07-15 | Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011528030A JP2011528030A (ja) | 2011-11-10 |
| JP2011528030A5 true JP2011528030A5 (enExample) | 2012-08-30 |
Family
ID=41011976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518009A Pending JP2011528030A (ja) | 2008-07-16 | 2009-07-15 | ピリミジルスルホンアミド誘導体およびケモカイン介在疾患処置のためのその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100016275A1 (enExample) |
| EP (1) | EP2315754A1 (enExample) |
| JP (1) | JP2011528030A (enExample) |
| KR (1) | KR20110031462A (enExample) |
| CN (1) | CN102159555A (enExample) |
| AR (1) | AR072818A1 (enExample) |
| AU (1) | AU2009272425B2 (enExample) |
| BR (1) | BRPI0915908A2 (enExample) |
| CA (1) | CA2730477A1 (enExample) |
| MX (1) | MX2011000402A (enExample) |
| RU (1) | RU2011101661A (enExample) |
| TW (1) | TW201006824A (enExample) |
| WO (1) | WO2010007427A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME01620B (me) | 2004-08-28 | 2014-09-20 | Astrazeneca Ab | Pirimidin sulfonamidni derivati kao modulatori hemokinskih receptora |
| SG186859A1 (en) | 2010-07-13 | 2013-02-28 | Astrazeneca Ab | New crystalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3-dihydroxy-1- methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide |
| DK3255043T3 (da) * | 2011-07-12 | 2021-03-29 | Astrazeneca Ab | N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorbenzylthio)pyrimidin-4-yl)-3-methylazetidin-1-sulfonamid som kemokinreceptormodulator |
| CA2859271A1 (en) * | 2012-02-07 | 2013-08-15 | F. Hoffmann-La Roche Ag | Novel azetidine derivatives |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| WO2017156270A1 (en) | 2016-03-11 | 2017-09-14 | Ardea Biosciences, Inc. | Cxcr-2 inhibitors for treating crystal arthropathy disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2540356A (en) * | 1949-03-12 | 1951-02-06 | Sharp & Dohme Inc | Sulfonamide derivatives |
| GB866843A (en) * | 1958-12-08 | 1961-05-03 | Ici Ltd | Sulphonamidopyrimidines |
| NL279406A (enExample) * | 1961-06-16 | |||
| NL127990C (enExample) * | 1962-12-29 | |||
| US3457278A (en) * | 1964-10-15 | 1969-07-22 | Geigy Chem Corp | Cyclopropyl-4-sulfanilamido-pyrimidines |
| US3452018A (en) * | 1966-08-29 | 1969-06-24 | American Home Prod | 1 - (2 - substituted - 6 - arylsulfonamidopyrimidin - 4 - yl)pyridinium hydroxide inner salts |
| US3673184A (en) * | 1970-09-02 | 1972-06-27 | Dainippon Pharmaceutical Co | Certain 2-substituted-5,8-dihydro-5-oxopyrido{8 2,3-d{9 pyrimidine-6-carboxylic acid derivatives |
| GB2359551A (en) * | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB0217431D0 (en) * | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| ATE381546T1 (de) * | 2002-08-24 | 2008-01-15 | Astrazeneca Ab | Pyrimidinderivate als modulatoren der aktivitut von chemokinrezeptoren |
| GB0401269D0 (en) * | 2004-01-21 | 2004-02-25 | Astrazeneca Ab | Compounds |
| GB0419235D0 (en) * | 2004-08-28 | 2004-09-29 | Astrazeneca Ab | Compounds |
| ME01620B (me) * | 2004-08-28 | 2014-09-20 | Astrazeneca Ab | Pirimidin sulfonamidni derivati kao modulatori hemokinskih receptora |
| JP2006137723A (ja) * | 2004-11-15 | 2006-06-01 | Kyowa Hakko Kogyo Co Ltd | スルホンアミド誘導体 |
-
2009
- 2009-07-15 RU RU2011101661/04A patent/RU2011101661A/ru not_active Application Discontinuation
- 2009-07-15 EP EP09785332A patent/EP2315754A1/en not_active Withdrawn
- 2009-07-15 TW TW098123883A patent/TW201006824A/zh unknown
- 2009-07-15 KR KR1020117000994A patent/KR20110031462A/ko not_active Withdrawn
- 2009-07-15 CN CN2009801361926A patent/CN102159555A/zh active Pending
- 2009-07-15 US US12/503,433 patent/US20100016275A1/en not_active Abandoned
- 2009-07-15 CA CA2730477A patent/CA2730477A1/en not_active Abandoned
- 2009-07-15 BR BRPI0915908A patent/BRPI0915908A2/pt not_active IP Right Cessation
- 2009-07-15 AU AU2009272425A patent/AU2009272425B2/en not_active Ceased
- 2009-07-15 WO PCT/GB2009/050856 patent/WO2010007427A1/en not_active Ceased
- 2009-07-15 JP JP2011518009A patent/JP2011528030A/ja active Pending
- 2009-07-15 MX MX2011000402A patent/MX2011000402A/es not_active Application Discontinuation
- 2009-07-16 AR ARP090102722A patent/AR072818A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011528030A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| CN111836805A (zh) | 吡啶衍生物及其用于治疗hiv感染的用途 | |
| JP2018515495A5 (enExample) | ||
| JP2014524442A5 (enExample) | ||
| JP2013519645A5 (enExample) | ||
| HRP20161696T4 (hr) | Tenofovir alafenamid hemifumarat | |
| JP2011528658A5 (enExample) | ||
| CA3023216A1 (en) | Compounds and compositions for inhibiting the activity of shp2 | |
| CN1227233C (zh) | 纯晶形的5－氯－3－(4－甲磺酰基苯基)－6′－甲基－[2,3′]联吡啶及其合成方法 | |
| MX2015004787A (es) | Compuestos antiviricos para el virus sincitial respiratorio. | |
| EP2760285A1 (en) | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof | |
| CN103249697A (zh) | 适用作多巴胺能稳定剂的普利多匹定(pridopidine)氘化类似物 | |
| JP2006504766A5 (enExample) | ||
| JP2020536893A5 (enExample) | ||
| JP2017531619A5 (enExample) | ||
| EA009941B1 (ru) | Имидазопиридинзамещённые тропановые производные, обладающие активностью антагониста ccr5 рецептора, для лечения вируса иммунодефицита человека (вич) и воспаления | |
| RU2022109286A (ru) | Кристаллическая форма гидрата свободного основания лорлатиниба | |
| JP2012533550A5 (enExample) | ||
| WO2018234978A1 (en) | Substituted 5-cyanoindole compounds and uses thereof | |
| CN116406355A (zh) | P38α促分裂原活化蛋白激酶抑制剂 | |
| CN101531653B (zh) | 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用 | |
| JP2008531558A5 (enExample) | ||
| JP2005521651A5 (enExample) | ||
| JP2016510768A5 (enExample) |